Tapestry, Inc. Free cash flow decreased by 78.2% to $225.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 99.1%, from $113.40M to $225.80M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -2.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $332.00M | -$11.60M | $608.00M | -$55.10M | $218.00M | -$197.70M | $551.30M | $71.60M | $365.80M | $54.40M | $803.70M | $78.80M | $209.80M | $93.90M | $475.10M | $113.40M | $411.50M | $80.20M | $1.04B | $225.80M |
| QoQ Change | — | -103.5% | >999% | -109.1% | +495.6% | -190.7% | +378.9% | -87.0% | +410.9% | -85.1% | >999% | -90.2% | +166.2% | -55.2% | +406.0% | -76.1% | +262.9% | -80.5% | >999% | -78.2% |
| YoY Change | — | — | — | — | -34.3% | <-999% | -9.3% | +229.9% | +67.8% | +127.5% | +45.8% | +10.1% | -42.6% | +72.6% | -40.9% | +43.9% | +96.1% | -14.6% | +118.4% | +99.1% |